NAD+ injection vs IV: what UK clinics differ on

Once you start looking at clinic NAD+, you hit a fork: drip or injection. This post explains how UK clinics differ on the two formats. It is editorial commentary. We do not state doses, and we do not recommend a route for any individual.

The basic difference

IV NAD+ is delivered straight into a vein, usually over several hours, as covered in IV NAD+ in the UK. A NAD+ injection is given into the fat layer (subcutaneous) or muscle (intramuscular) and takes a few moments rather than an afternoon. Both are compounded by the clinic or its pharmacy. The molecule is the same; the delivery and the timeline are not.

The trade-off clinics describe is straightforward. The drip can deliver a larger amount in one sitting but costs more and takes hours. The injection is quick and usually cheaper per visit but delivers less per administration, so it is typically offered as a more frequent course rather than a one-off.

Time, comfort and cost

For many people the deciding factor is practical. An IV session means committing several hours and sitting with a cannula in place; the slow rate is deliberate, because infusion-related sensations track how fast NAD+ is delivered, a point we cover in NAD+ side-effects. An injection is over in moments, which some find more tolerable and easier to fit around work.

On cost, the injection generally sits below the drip per administration, but because clinics schedule injections more often, the total course cost is not always lower. We set out the full ladder in NAD+ cost in the UK.

Same regulatory position

This is the part that surprises people. Whether NAD+ is dripped or injected, the UK regulatory position is the same: it is not a licensed medicine, because it is not marketed under a Marketing Authorisation. Both formats sit under private clinical service regulation. The clinic should hold CQC registration in England (or the equivalent in the devolved nations), the practitioner should be GMC or GPhC registered, and any separate compounding pharmacy should be GPhC registered.

That shared status matters because it means the choice between injection and IV is a clinical and practical one, not a regulatory upgrade. Neither route confers medicine status on NAD+.

What the evidence does and does not say

The human evidence for raising NAD+ is early and route-dependent across both formats. Studies suggest NAD+ levels can be influenced by clinical administration; studies do not establish that either format produces the anti-ageing outcomes used in marketing. There are no large long-term randomised trials comparing injection and IV on health outcomes. Anyone telling you one format is proven superior is going beyond the evidence.

What to ask a clinic

Reasonable, non-clinical questions before booking either format include who administers it and what their registration is, what the clinic’s CQC status is, how the product is compounded and by which pharmacy, and what the full course (not single session) costs. A suitably qualified healthcare professional at the clinic should be screening your suitability rather than simply selling a package.

Read next

The NAD+ sub-hub maps every route. For the drip in detail, see IV NAD+ in the UK, and for named providers, London IV NAD+ clinics. If you would rather avoid clinics entirely, NAD+ supplements in the UK covers the oral precursor route.